Lantern Pharma Inc
$ 2.78
-0.71%
06 Aug - close price
- Market Cap 35,725,600 USD
- Current Price $ 2.78
- High / Low $ 2.90 / 2.71
- Stock P/E N/A
- Book Value 0.31
- EPS -1.45
- Next Earning Report 2026-08-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.73 %
- ROE -1.57 %
- 52 Week High 5.25
- 52 Week Low 1.11
About
Lantern Pharma Inc., a clinical-stage biotechnology company, focuses on developing precision cancer therapies using artificial intelligence, genomics, and machine learning. The company is headquartered in Dallas, Texas.
Analyst Target Price
$17.50
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-15 | 2026-03-30 | 2025-11-12 | 2025-08-13 | 2025-05-15 | 2025-03-27 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-18 | 2023-11-08 | 2023-08-09 |
| Reported EPS | -0.3 | -0.36 | -0.39 | -0.4 | -0.42 | -0.54 | -0.42 | -0.46 | -0.51 | -0.39 | -0.29 | -0.44 |
| Estimated EPS | -0.36 | -0.46 | -0.47 | -0.48 | -0.43 | -0.51 | -0.56 | -0.55 | -0.43 | -0.4 | -0.48 | -0.45 |
| Surprise | 0.06 | 0.1 | 0.08 | 0.08 | 0.01 | -0.03 | 0.14 | 0.09 | -0.08 | 0.01 | 0.19 | 0.01 |
| Surprise Percentage | 16.6667% | 21.7391% | 17.0213% | 16.6667% | 2.3256% | -5.8824% | 25% | 16.3636% | -18.6047% | 2.5% | 39.5833% | 2.2222% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-12 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LTRN
2026-08-04 13:40:08
Empery Asset Management LP and Ryan M. Lane have disclosed a 9.99% beneficial ownership stake in Lantern Pharma Inc. (LTRN) through a Schedule 13G filing. This stake includes 1,322,551 shares of common stock, with 479,882 shares issuable upon the exercise of warrants, all subject to a 9.99% beneficial ownership limitation. The ownership percentage is calculated based on 12,758,872 shares outstanding as of May 31, 2026.
2026-08-04 07:36:45
Lantern Pharma Inc. (NASDAQ:LTRN) has spun out its AI platform, previously known as withZeta.ai, into a new entity called Open-Medicine AI. This new company will operate independently with its own funding and valuation path, licensing Lantern Pharma's AI models, data, and algorithms. Open-Medicine AI aims to revolutionize medicine discovery and development, expanding beyond oncology into other disease areas.
2026-08-03 21:40:58
Lantern Pharma has formed Open-Medicine AI as a separate entity to commercialize its multi-agent withZeta.ai platform. This new company will expand the AI co-scientist platform beyond oncology, supported by AI Centers of Excellence. The move is strategically positioned to capitalize on the projected $10B global AI drug discovery market by 2030.
2026-08-03 11:13:49
Lantern Pharma (LTRN) has established Open-Medicine AI (OMAI) as a separate company to commercialize and expand its multi-agent AI co-scientist platform, initially proven in oncology, into broader disease areas. This strategic move, supported by licensing agreements, aims to capitalize on the rapidly growing AI drug discovery market, projected to exceed $10 billion by 2030. OMAI will operate with independent funding and a distinct valuation path, while maintaining strategic alignment with Lantern Pharma's clinical programs.
2026-08-03 11:13:49
Lantern Pharma Inc. (NASDAQ:LTRN) announced the creation of Open-Medicine AI, a new entity to house its multi-agentic AI platform previously known as withZeta.ai. This spin-out involves commercial licensing agreements between the two companies and aims to allow Open-Medicine AI to pursue dedicated funding and a distinct valuation path. The platform, initially developed for oncology research, will expand into additional disease areas, leveraging its AI Center of Excellence in India alongside its Dallas team.
2026-08-03 04:40:58
Lantern Pharma (Nasdaq: LTRN) has officially launched Open-Medicine AI (OMAI) as a separate company, signing commercial licensing agreements for Lantern's AI models, data, and algorithms. OMAI will commercialize and expand the multi-agent AI co-scientist platform, previously known as withZeta.ai, beyond oncology into other disease areas. This move aims to position OMAI for independent growth in the projected $10 billion global AI drug discovery market by 2030, while maintaining strategic alignment with Lantern Pharma.
